SpringWorks Therapeutics Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates at 43rd Annual J.P. Morgan Healthcare Conference
Portfolio Pulse from
SpringWorks Therapeutics announced its preliminary financial results for Q4 and full year 2024 at the J.P. Morgan Healthcare Conference. The company reported $61.5 million in Q4 and $172.0 million in full year U.S. net product revenues for OGSIVEO (nirogacestat).
January 13, 2025 | 11:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
SpringWorks Therapeutics reported strong preliminary financial results for Q4 and full year 2024, with significant revenues from OGSIVEO (nirogacestat).
The reported revenues of $61.5 million for Q4 and $172.0 million for the full year indicate strong sales performance of OGSIVEO (nirogacestat), which is likely to positively impact SpringWorks Therapeutics' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100